Informações:
Falhas:
ID
13508
Descrição
Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible (PAZOPANIB-AML) https://clinicaltrials.gov/ct2/show/NCT01361334 Principal Investigator: PD Dr. Torsten Kessler, University Hospital Muenster, Germany
Link
https://clinicaltrials.gov/ct2/show/NCT01361334
Palavras-chave
Versões (3)
- 14/08/2015 14/08/2015 - Martin Dugas
- 06/01/2016 06/01/2016 -
- 11/02/2016 11/02/2016 -
Transferido a
11 de fevereiro de 2016
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
End of study AML Pazopanib NCT01361334
End of study AML Pazopanib NCT01361334
- StudyEvent: SE
Similar models
End of study AML Pazopanib NCT01361334
- StudyEvent: SE
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Patient ID (derived)
Item
Patient ID (derived)
text
C2348585 (UMLS CUI [1])
Studienabbruch: Datum
Item
End of study: date
date
C2985813 (UMLS CUI [1])
CL Item
T (1)
CL Item
TM (2)
CL Item
M (3)
Item
End of study: withdrawal of informed consent
text
C0021430 (UMLS CUI [1])
CL Item
End of study: withdrawal of informed consent through patient of legal representative (1)
Item
End of study: Violation of eligibility criteria
text
C1516637 (UMLS CUI [1])
Code List
End of study: Violation of eligibility criteria
CL Item
nachträgliche Feststellung durch den Prüfarzt, dass Einschlusskriterien nicht erfüllt sind ... (1)
CL Item
adverse event(s) (1)
CL Item
Death (1)
CL Item
lost to follow up (1)
CL Item
progressive disease (1)
CL Item
relapse (1)
Studienabbruch: Neue anti-leuk Ther - Datum
Item
End of study: new anti-leukemic treatment date
date
C1299575 (UMLS CUI [1,1])
C0011008 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])
Item
End of study: new anti-leukemic treatment date status
text
Code List
End of study: new anti-leukemic treatment date status
CL Item
T (1)
CL Item
TM (2)
CL Item
M (3)
Studienabbruch: Neue anti-leukäm. Therapie - Text
Item
End of study: treatment modification, new antileukemic treatment
text
C1299575 (UMLS CUI [1])
CL Item
other reason (9)
Studienabbruch: Anderer Gund - Text
Item
End of study: other reason - text
text
Item
End of study: complete remission
text
C0677874 (UMLS CUI [1])
CL Item
CR (1)
CL Item
Complete remission with incomplete platelet recovery (1)
CL Item
Complete response with incomplete bone marrow recovery (1)
CL Item
Partial remission (PR) (1)
CL Item
Stable disease (1)
CL Item
Progression (1)
CL Item
relapse (1)
CL Item
unknown (9)
CL Item
other (9)
Studienabbruch: Sonstiges - Text
Item
End of study: other (Text)
text
Studienabbruch: Signatur - Datum
Item
End of study: signature date
date
C0807937 (UMLS CUI [1])
Item
End of study: signature - date status
text
C2985875 (UMLS CUI [1])
CL Item
T (1)
CL Item
TM (2)
CL Item
M (3)
Item
End of study: signature of investigator
text
C2346576 (UMLS CUI [1])
CL Item
yes (1)
CL Item
no (0)
Kommentar Studienabbruch
Item
End of study: comment
text
C0947611 (UMLS CUI [1])
Item Group
End of study: violated inclusion/exclusion criteria
C1518546 (UMLS CUI-1)
C1516637 (UMLS CUI-2)
C1516637 (UMLS CUI-2)
Item
End of study: violated inclusion/exclusion criteria Code
text
C1518546 (UMLS CUI [1,1])
C1516637 (UMLS CUI [1,2])
C1516637 (UMLS CUI [1,2])
Code List
End of study: violated inclusion/exclusion criteria Code
CL Item
EIN01 (1)
CL Item
EIN02 (2)
CL Item
EIN03 (3)
CL Item
EIN04 (4)
CL Item
EIN05 (5)
CL Item
EIN06 (6)
CL Item
EIN07 (7)
CL Item
EIN08 (8)
CL Item
EIN09 (9)
CL Item
AUS01 (10)
CL Item
AUS02 (11)
CL Item
AUS03 (12)
CL Item
AUS04 (13)
CL Item
AUS05 (14)
CL Item
AUS06 (15)
CL Item
AUS07 (16)
CL Item
AUS08 (17)
CL Item
AUS09 (18)
CL Item
AUS10 (19)
CL Item
AUS11 (20)
CL Item
AUS12 (21)
CL Item
AUS13 (22)
CL Item
AUS14 (23)
CL Item
AUS15 (24)
Item Group
End of study: adverse event(s)
C1518546 (UMLS CUI-1)
C0877248 (UMLS CUI-2)
C0877248 (UMLS CUI-2)
Studienabbruch: Unerwünschte(s) Ereignis(se)-AE-Nr
Item
End of study: adverse event(s) Nr
integer
C1518546 (UMLS CUI [1,1])
C0877248 (UMLS CUI [1,2])
C0877248 (UMLS CUI [1,2])